InSite, Merck, Mylan, Pfizer ophthalmic news

InSite, Merck and Pfizer filed suit in the U.S. District Court for the District of New Jersey against Mylan alleging its ANDA filing for a generic version of AzaSite 1% azithromycin ophthalmic solution infringes U.S. Patent nos. 6,861,411; 6,239,113; 6,569,443; and 7,056,893. The ANDA filing contained a paragraph IV certification claiming that the '411, '113, '443 and '893 patents are invalid and/or unenforceable and that certain claims of the '411, '443 and '893 patents would not be infringed by the manufacture, use, importation, sale or offer for sale of the Mylan product. ...